Transcutaneous Vagal Nerve Stimulation Alone or in Combination With Radiotherapy Stimulates Lung Tumor Infiltrating Lymphocytes But Fails to Suppress Tumor Growth.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2021
Historique:
received: 08 09 2021
accepted: 03 11 2021
entrez: 20 12 2021
pubmed: 21 12 2021
medline: 17 2 2022
Statut: epublish

Résumé

The combination of radiotherapy (RT) with immunotherapy represents a promising treatment modality for non-small cell lung cancer (NSCLC) patients. As only a minority of patients shows a persistent response today, a spacious optimization window remains to be explored. Previously we showed that fractionated RT can induce a local immunosuppressive profile. Based on the evolving concept of an immunomodulatory role for vagal nerve stimulation (VNS), we tested its therapeutic and immunological effects alone and in combination with fractionated RT in a preclinical-translational study. Lewis lung carcinoma-bearing C57Bl/6 mice were treated with VNS, fractionated RT or the combination while a patient cohort with locally advanced NSCLC receiving concurrent radiochemotherapy (ccRTCT) was enrolled in a clinical trial to receive either sham or effective VNS daily during their 6 weeks of ccRTCT treatment. Preclinically, VNS alone or with RT showed no therapeutic effect yet VNS alone significantly enhanced the activation profile of intratumoral CD8

Identifiants

pubmed: 34925341
doi: 10.3389/fimmu.2021.772555
pmc: PMC8671299
doi:

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

772555

Informations de copyright

Copyright © 2021 Reijmen, De Mey, Van Damme, De Ridder, Gevaert, De Blay, Bouwens, Collen, Decoster, De Couck, Laoui, De Grève, De Ridder, Gidron and Goyvaerts.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Science. 2013 Jul 12;341(6142):1236361
pubmed: 23846904
Clin Cancer Res. 2015 Sep 15;21(18):4073-4085
pubmed: 25922428
Auton Neurosci. 2012 Jan 26;166(1-2):96-9
pubmed: 22070982
Regul Pept. 2012 Nov 10;179(1-3):101-8
pubmed: 22982142
Nat Commun. 2015 Mar 10;6:6426
pubmed: 25756236
J Clin Invest. 2019 Dec 2;129(12):5537-5552
pubmed: 31566578
Cancer Res. 2010 Sep 15;70(18):7042-52
pubmed: 20823155
Science. 2011 Mar 25;331(6024):1565-70
pubmed: 21436444
J Clin Invest. 1998 Aug 1;102(3):465-72
pubmed: 9691082
Int J Radiat Oncol Biol Phys. 2021 Sep 1;111(1):272-283
pubmed: 33865948
Cancer Immunol Immunother. 2013 Sep;62(9):1439-51
pubmed: 23760662
Immunol Lett. 2018 Oct;202:38-43
pubmed: 30077536
Science. 2011 Oct 7;334(6052):98-101
pubmed: 21921156
Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):11008-13
pubmed: 18669662
Nat Rev Cancer. 2006 Mar;6(3):240-8
pubmed: 16498446
Stem Cells. 2017 Dec;35(12):2351-2365
pubmed: 29044882
J Immunol. 2009 Mar 1;182(5):2753-65
pubmed: 19234170
Brain Behav Immun. 2007 Aug;21(6):736-45
pubmed: 17467231
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Nat Rev Cancer. 2012 Mar 22;12(4):265-77
pubmed: 22437871
Anticancer Res. 2004 Mar-Apr;24(2B):1003-9
pubmed: 15161056
J Ovarian Res. 2015 Jun 17;8:39
pubmed: 26077607
Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):6086-6091
pubmed: 28533380
Nature. 2021 May;593(7860):506-509
pubmed: 34035530
Regul Pept. 2008 Nov 29;151(1-3):35-42
pubmed: 18499282
Front Immunol. 2018 Feb 06;9:164
pubmed: 29479349
Cancer Immunol Immunother. 2020 Feb;69(2):307-314
pubmed: 31912230
Front Immunol. 2017 Mar 13;8:229
pubmed: 28348554
Nat Rev Cancer. 2018 May;18(5):313-322
pubmed: 29449659
Front Immunol. 2019 May 22;10:1147
pubmed: 31191529
Lung Cancer. 2017 Sep;111:176-181
pubmed: 28838390
Tumour Biol. 2011 Aug;32(4):689-95
pubmed: 21409421
J Thorac Oncol. 2021 Jul;16(7):1099-1117
pubmed: 33839365
Oncotarget. 2016 Jul 12;7(28):44534-44544
pubmed: 27322208
Cancer Res. 2015 Sep 15;75(18):3800-11
pubmed: 26208901
J Immunol Res. 2018 May 8;2018:4874193
pubmed: 29854838
J Neurosci. 2019 May 1;39(18):3454-3469
pubmed: 30804093
Amino Acids. 2013 Jul;45(1):55-71
pubmed: 22160285
Sci Rep. 2021 Apr 27;11(1):9020
pubmed: 33907270
Sci Rep. 2016 Dec 15;6:39247
pubmed: 27976733
Curr Opin Immunol. 2014 Apr;27:16-25
pubmed: 24531241
Cell. 2008 May 30;133(5):775-87
pubmed: 18510923
PLoS One. 2020 Nov 10;15(11):e0242173
pubmed: 33170901
Clin Cancer Res. 2012 Mar 1;18(5):1201-6
pubmed: 22186256
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Front Oncol. 2020 Oct 16;10:547013
pubmed: 33178579
PLoS One. 2015 May 07;10(5):e0126496
pubmed: 25950176
Dis Esophagus. 2010 Jul;23(5):422-9
pubmed: 20002703
Nat Commun. 2016 Feb 04;7:10517
pubmed: 26841680
Cell. 2017 May 4;169(4):750-765.e17
pubmed: 28475900
J Thorac Oncol. 2021 Jul;16(7):1086-1098
pubmed: 33845212
Immune Netw. 2009 Aug;9(4):122-6
pubmed: 20157598
Lancet. 2001 Feb 17;357(9255):539-45
pubmed: 11229684
Eur J Nucl Med Mol Imaging. 2008 May;35(5):999-1007
pubmed: 18180921
Cancer Immunol Immunother. 2014 Nov;63(11):1115-28
pubmed: 25307152
J Immunotoxicol. 2015 Jul-Sep;12(3):300-7
pubmed: 25140864
Front Immunol. 2018 Jun 11;9:1310
pubmed: 29942309
J Immunol. 2010 Jun 15;184(12):6833-42
pubmed: 20483762
Trends Immunol. 2010 Jun;31(6):220-7
pubmed: 20538542
Annu Rev Immunol. 2012;30:313-35
pubmed: 22224768
Nature. 2011 Dec 21;480(7378):480-9
pubmed: 22193102
Cell. 2016 Jan 28;164(3):343-4
pubmed: 26824649
J Immunother. 2012 May;35(4):299-308
pubmed: 22495387
Clin Cancer Res. 2018 Aug 15;24(16):3857-3866
pubmed: 29716923
Cold Spring Harb Perspect Biol. 2017 Jun 1;9(6):
pubmed: 28108486
Nat Med. 2018 Aug;24(8):1277-1289
pubmed: 29988129
Clin Cancer Res. 2014 Jan 1;20(1):44-55
pubmed: 24045181
Nat Neurosci. 2019 Aug;22(8):1289-1305
pubmed: 31285612
Onco Targets Ther. 2019 May 29;12:4235-4244
pubmed: 31239702
Biomed Res Int. 2014;2014:751392
pubmed: 25110692
Nat Rev Cancer. 2015 Sep;15(9):563-72
pubmed: 26299593
Psychosom Med. 2015 May;77(4):346-55
pubmed: 25886831

Auteurs

Eva Reijmen (E)

Laboratory for Molecular and Cellular Therapy, Department of Biomedical Sciences, Vrije Universiteit Brussel, Brussels, Belgium.

Sven De Mey (S)

Department of Radiotherapy, Oncology Centre University Hospital Brussels (Universitair Ziekenhuis (UZ) Brussel), Brussels, Belgium.

Helena Van Damme (H)

Myeloid Cell Immunology Lab, Vlaams Instituut voor Biotechnologie (VIB) Center for Inflammation Research, Brussels, Belgium.
Lab of Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium.

Kirsten De Ridder (K)

Laboratory for Molecular and Cellular Therapy, Department of Biomedical Sciences, Vrije Universiteit Brussel, Brussels, Belgium.

Thierry Gevaert (T)

Department of Radiotherapy, Oncology Centre University Hospital Brussels (Universitair Ziekenhuis (UZ) Brussel), Brussels, Belgium.

Emmy De Blay (E)

Cell Differentiation Lab, Vrije Universiteit Brussel, Brussels, Belgium.

Luc Bouwens (L)

Cell Differentiation Lab, Vrije Universiteit Brussel, Brussels, Belgium.

Christine Collen (C)

Department of Radiotherapy, Oncology Centre University Hospital Brussels (Universitair Ziekenhuis (UZ) Brussel), Brussels, Belgium.

Lore Decoster (L)

Laboratory of Medical and Molecular Oncology (LMMO), Department of Medical Oncology, Oncologisch Centrum, Universitair Ziekenhuis (UZ) Brussel, Vrije Universiteit Brussel (VUB), Brussels, Belgium.

Marijke De Couck (M)

Department of Public Health, Mental Health and Wellbeing Research Group, Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Brussels, Belgium.
Faculty of Health Care, University College Odisee, Aalst, Belgium.

Damya Laoui (D)

Myeloid Cell Immunology Lab, Vlaams Instituut voor Biotechnologie (VIB) Center for Inflammation Research, Brussels, Belgium.
Lab of Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium.

Jacques De Grève (J)

Laboratory of Medical and Molecular Oncology (LMMO), Department of Medical Oncology, Oncologisch Centrum, Universitair Ziekenhuis (UZ) Brussel, Vrije Universiteit Brussel (VUB), Brussels, Belgium.

Mark De Ridder (M)

Department of Radiotherapy, Oncology Centre University Hospital Brussels (Universitair Ziekenhuis (UZ) Brussel), Brussels, Belgium.

Yori Gidron (Y)

Faculty of Social Welfare and Health Sciences, University of Haifa, Haifa, Israel.

Cleo Goyvaerts (C)

Laboratory for Molecular and Cellular Therapy, Department of Biomedical Sciences, Vrije Universiteit Brussel, Brussels, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH